Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized study of tipifarnib versus best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in subjects 70 years or older (Farnesyl transferase Inhibition Global Human trials AML 301 [F.I.G.H.T. AML 301])

Next Previous
X
Search
Trial Profile

A randomized study of tipifarnib versus best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in subjects 70 years or older (Farnesyl transferase Inhibition Global Human trials AML 301 [F.I.G.H.T. AML 301])

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms FIGHT-AML-301
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 27 Mar 2019 This trial has been completed in Ireland, according to European Clinical Trials Database.
    • 27 Apr 2010 Actual number of patients (457) added as reported by ClinicalTrials.gov.
    • 19 Sep 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top